[1] Cardenas A,Arroyo V. Refractory ascites. Dig Dis,2005,23（1）:30-38.
[2] 王国才,张国,梁扩寰,等. 特立加压素,垂体后叶素对正常及门脉高压兔门脉血流动力学影响的研究. 中华消化杂志,2002,22（10）:595-597.
[3] 黄加权,李艳辉,黄铁军,等. 三七皂苷联合特利加压素治疗肝硬化腹水的研究. 中国药师,2007,10（9）:861-863.
[4] Krag A,Moller S,Henriksen JH,et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology,2007,46:1863-1871.
[5] 李光明,范建高. 2010年欧洲肝病学会肝硬化腹水、自发性细菌性腹膜炎、肝肾综合征指南解读. 中国医学前沿杂志（电子版）,2011,1:1.
[6] 孙波,慎睿哲,吴云林. 血管活性药物治疗肝肾综合征. 胃肠病,2005,10（2）:127-128.
[7] 邹建洲,滕杰,丁小强,等. 托拉塞米注射液治疗水肿性疾病安全性和利尿效果研究. 中华肾脏病杂志,2005,12:2.
[8] Rodriguez-pere ZF,Groszmann RJ. Pharmacologic treatment of portal hypertension. Gastroenterol Clinics North Am,1992,21：15-40.
[9] Nilsson G,Lindblom P,Ohlin N,et al.Pharmacokinetics of terlipressin after single I.V.doses to healthy volunteers. Drugs Experiment Clin Res,1990,16:307-314.
[10] Hansen EF,Bendtsen F,Brinch K,et al. Endoscopic Doppler ultrasound for measuremen of azygos blood flow.Validation against thermodilution and assessment of pharmacological effects of terlipressin in portal hypertension. Scand J Gastroenterol,2001,36:318-325.
[11] Kiszka-Kanowitz M,Henriksen JH,Hansen EF,et al. Effect of terlipression on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol,2004,39:486-492.
[12] Moller S,Hansen EF,Becker U,et al. Central and systemic haemodynamic effects of terlipressin in hypertensive pations. Liver,2000,20:51-59. |
